Pharmacosmos Acquires G1 Therapeutics

MorphoSys Acquires Constellation Pharmaceuticals for $1.7B

June 2, 2021

Biotechnology

MorphoSys AG has agreed to acquire Constellation Pharmaceuticals for $34.00 per share in cash, valuing the transaction at approximately $1.7 billion. The deal strengthens MorphoSys' hematology-oncology pipeline by adding Constellation's mid- to late-stage candidates (pelabresib/CPI-0610 and CPI-0209) and is supported by a strategic funding partnership with Royalty Pharma that provides significant upfront and milestone funding.

GlaxoSmithKline Acquires Sierra Oncology for $1.9bn

April 13, 2022

Biotechnology

GlaxoSmithKline plc (GSK) has agreed to acquire late-stage biopharmaceutical company Sierra Oncology for $55 per share in cash, representing an approximate equity value of $1.9 billion. The acquisition, expected to close in Q3 2022 subject to customary approvals, brings momelotinib — a late-stage JAK/ACVR1 inhibitor with demonstrated benefit on symptoms, splenic response and anaemia in myelofibrosis — into GSK's haematology portfolio to strengthen its specialty medicines capability and global commercial reach.

Ionis Pharmaceuticals to Acquire Remaining Stake in Akcea Therapeutics

August 31, 2020

Biotechnology

Ionis Pharmaceuticals agreed to acquire the approximately 24% of Akcea Therapeutics it does not already own for $18.15 per share in cash, implying a fully diluted transaction value of about $500 million. The deal will be executed via a tender offer followed by a second-step merger, and Ionis expects to complete the transaction in Q4 2020 to consolidate Akcea's pipeline, commercial products and cash while realizing cost synergies.

Pharmacosmos A/S Acquires AbFero Pharmaceuticals, Inc.

November 11, 2021

Pharmaceuticals

Pharmacosmos A/S (Pharmacosmos Group) has agreed to acquire all assets of Boston-based clinical-stage AbFero Pharmaceuticals, Inc. under a share purchase agreement for up to $225 million including upfront, milestone, and royalty components. The acquisition adds AbFero’s SP-420 iron chelation program to Pharmacosmos’ iron-metabolism-focused R&D and commercial capabilities to accelerate development and commercialization for transfusional iron overload and related indications.

Gilead Sciences Acquires CymaBay Therapeutics for $4.3 Billion

February 12, 2024

Biotechnology

Gilead Sciences has completed the acquisition of CymaBay Therapeutics for approximately $4.3 billion, paying $32.50 per share in cash. The deal adds CymaBay's investigational PPARδ agonist seladelpar for primary biliary cholangitis (PBC) to Gilead's liver-disease portfolio and is expected to accelerate development and potential commercialization of the therapy.

Galecto Inc. Merges with San Diego-based PharmAkea, Inc.

January 9, 2020

Pharmaceuticals

Copenhagen-headquartered Galecto Inc. (a Novo Seeds portfolio company) has merged with San Diego-based PharmAkea, Inc. The combined clinical-stage company will retain the Galecto name, be incorporated in the United States, and combine complementary pipelines in fibrosis and oncology to accelerate development of small-molecule and galectin-targeting therapeutics.